1
|
Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment. Cancers (Basel) 2022; 14:cancers14030625. [PMID: 35158893 PMCID: PMC8833668 DOI: 10.3390/cancers14030625] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 01/14/2022] [Accepted: 01/19/2022] [Indexed: 01/01/2023] Open
Abstract
Hyperthermia (HT) is a cancer treatment modality which targets malignant tissues by heating to 40-43 °C. In addition to its direct antitumor effects, HT potently sensitizes the tumor to radiotherapy (RT) and chemotherapy (CT), thereby enabling complete eradication of some tumor entities as shown in randomized clinical trials. Despite the proven efficacy of HT in combination with classic cancer treatments, there are limited international standards for the delivery of HT in the clinical setting. Consequently, there is a large variability in reported data on thermometric parameters, including the temperature obtained from multiple reference points, heating duration, thermal dose, time interval, and sequence between HT and other treatment modalities. Evidence from some clinical trials indicates that thermal dose, which correlates with heating time and temperature achieved, could be used as a predictive marker for treatment efficacy in future studies. Similarly, other thermometric parameters when chosen optimally are associated with increased antitumor efficacy. This review summarizes the existing clinical evidence for the prognostic and predictive role of the most important thermometric parameters to guide the combined treatment of RT and CT with HT. In conclusion, we call for the standardization of thermometric parameters and stress the importance for their validation in future prospective clinical studies.
Collapse
|
2
|
Lee SY, Fiorentini G, Szasz AM, Szigeti G, Szasz A, Minnaar CA. Quo Vadis Oncological Hyperthermia (2020)? Front Oncol 2020; 10:1690. [PMID: 33014841 PMCID: PMC7499808 DOI: 10.3389/fonc.2020.01690] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Accepted: 07/29/2020] [Indexed: 12/19/2022] Open
Abstract
Heating as a medical intervention in cancer treatment is an ancient approach, but effective deep heating techniques are lacking in modern practice. The use of electromagnetic interactions has enabled the development of more reliable local-regional hyperthermia (LRHT) techniques whole-body hyperthermia (WBH) techniques. Contrary to the relatively simple physical-physiological concepts behind hyperthermia, its development was not steady, and it has gone through periods of failures and renewals with mixed views on the benefits of heating seen in the medical community over the decades. In this review we study in detail the various techniques currently available and describe challenges and trends of oncological hyperthermia from a new perspective. Our aim is to describe what we believe to be a new and effective approach to oncologic hyperthermia, and a change in the paradigm of dosing. Physiological limits restrict the application of WBH which has moved toward the mild temperature range, targeting immune support. LRHT does not have a temperature limit in the tumor (which can be burned out in extreme conditions) but a trend has started toward milder temperatures with immune-oriented goals, developing toward immune modulation, and especially toward tumor-specific immune reactions by which LRHT seeks to target the malignancy systemically. The emerging research of bystander and abscopal effects, in both laboratory investigations and clinical applications, has been intensified. Our present review summarizes the methods and results, and discusses the trends of hyperthermia in oncology.
Collapse
Affiliation(s)
- Sun-Young Lee
- Department of Radiation Oncology, Chonbuk National University Hospital, Jeonbuk, South Korea
| | | | - Attila Marcell Szasz
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
| | - Gyula Szigeti
- Innovation Center, Semmelweis University, Budapest, Hungary
| | - Andras Szasz
- Biotechnics Department, St. Istvan University, Godollo, Hungary
| | - Carrie Anne Minnaar
- Department of Radiation Oncology, Wits Donald Gordon Medical Center, Johannesburg, South Africa
| |
Collapse
|
3
|
Harima Y, Nagata K, Harima K, Ostapenko VV, Tanaka Y, Sawada S. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. Int J Hyperthermia 2009; 25:338-43. [DOI: 10.1080/02656730903092018] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Ohguri T, Imada H, Yahara K, Kakeda S, Tomimatsu A, Kato F, Nomoto S, Terashima H, Korogi Y. Effect of 8-MHz radiofrequency-capacitive regional hyperthermia with strong superficial cooling for unresectable or recurrent colorectal cancer. Int J Hyperthermia 2009; 20:465-75. [PMID: 15277020 DOI: 10.1080/02656730310001657729] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
A well-known disadvantage of a radiofrequency-capacitive device for deep-seated tumours is preferential heating of the subcutaneous fat tissue. The authors previously developed the hyperthermia with their own external cooling unit and achieved strong superficial cooling, and reported its usefulness for the reduction of the preferential heating. The purpose of the present study was to evaluate the effect of hyperthermia with strong superficial cooling on the treatment results for unresectable or recurrent colorectal cancers. From 1986 to 2002, 44 patients with primary unresectable or locally recurrent colorectal cancer treated with thermoradiotherapy were analysed retrospectively. The patients with obesity as a subcutaneous fat thickness more than 3 cm, a high age or other serious complications did not undergo therapy. The results were compared between 17 cases with strong superficial cooling treated after 1997 (Group A) and 27 cases without strong superficial cooling treated before 1996 (Group B). Significant differences in thermometry data of T(max), T(ave) and T(min) were noted between Groups A (45.3, 44.4 and 43.6 degrees C, respectively) and B (42.9, 42.0 and 41.1 degrees C, respectively) (p<0.01). Complete response plus partial response rates were better for Group A than for Group B (59 versus 26%, p = 0.05). Multivariate analysis by logistic regression to evaluate the effects of certain factors on complete response plus partial response was strongly correlated with strong superficial cooling (p<0.05). The median survival times for overall survival were 24.3 months for Group A and 17.1 months for Group B (p<0.05). Eight-megahertz radiofrequency-capacitive regional hyperthermia with strong superficial cooling is potentially useful for improving treatment results in unresectable or recurrent colorectal cancers.
Collapse
Affiliation(s)
- T Ohguri
- Department of Radiology, University of Occupational and Environmental Health, Iseigaoka 1-1, Yahatanisi-ku, Kitakyushu-shi 807-8555, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
De Haas-Kock DFM, Buijsen J, Pijls-Johannesma M, Lutgens L, Lammering G, van Mastrigt GAPG, De Ruysscher DKM, Lambin P, van der Zee J. Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. Cochrane Database Syst Rev 2009:CD006269. [PMID: 19588384 DOI: 10.1002/14651858.cd006269.pub2] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Surgery has been the treatment of choice for patients with rectal cancer. For locally advanced cancer results were poor, with high rates of locoregional recurrences and poor overall survival data. Adding (chemo)radiotherapy upfront improved results mainly in locoregional control. Adding hyperthermia to radiotherapy preoperatively might have an equivalent beneficial effect. OBJECTIVES To quantify the potential beneficial effect of thermo radiation compared to chemo-radiation with respect to pathological complete responses, overall survival and toxicity in rectal cancer therapy. SEARCH STRATEGY We identified the relevant phase II and III randomised controlled trials in any language trough electronic searches May 2007 of the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2007), the Cochrane Colorectal Cancer Groups Specialised Register, MEDLINE (from 1966), EMBASE (from 1974), CINAHL (from 1982). Furthermore, various trial databases were searched for the identification of recent completed and ongoing trials (metaRegister of Controlled Trials, Cancer Research UK, Cancer.gov, The Eastern Cooperative Oncology Group Trials Database). All studies identified until May 2007 were considered for inclusion in the present study. SELECTION CRITERIA Only phase II and III randomised controlled clinical trials were included in the analysis. DATA COLLECTION AND ANALYSIS All identified studies were assessed by two independent reviewers. A weighted estimate of the treatment effect was computed for 2, 3, 4 and 5-year survival, for local tumour recurrence, severe acute and late toxicity and complete tumour response (CR). CR was defined either clinically by disappearance of all pretreatment signs of local tumour or pathologically by microscopically free margins. The risk ratio (RR) and hazard ratio (HR) were used. Analyses were performed with the Reference Manager (RevMan). MAIN RESULTS Six RCTs published between 1990 and 2007 were identified. A total number of 520 patients was treated, 258 in the radiotherapy only arm (RT) and 262 in the radiotherapy-hyperthermia arm (RHT). Four studies (424 patients) reported overall survival (OS) rates. After 2 years, OS was significantly better in the RHT group (HR 2.06; 95% CI 1.33-3.17; p=.001), but this difference disappeared after a longer period (3, 4 and 5 year OS). All but one studies reported CR rates. A significant higher CR rate was observed in the RHT group (RR 2.81; 95% CI 1.22-6.45; p=.01). Only 2 studies reported on acute toxicity. In these 2 studies no significant differences were observed between the RT and the RHT group. Late toxicity data were not reported. AUTHORS' CONCLUSIONS Further studies are needed to compare chemoradiation versus thermoradiation versus chemoradiation plus hyperthermia in well selected/conducted and quality controlled randomised trials.
Collapse
Affiliation(s)
- Danielle F M De Haas-Kock
- Department of Radiation Oncology (MAASTRO clinic), GROW Research Institute, University Medical Center, dr. Tanslaan 12, Maastricht, Netherlands, 6229 ET
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Ohguri T, Imada H, Kato F, Yahara K, Morioka T, Nakano K, Korogi Y. Radiotherapy with 8 MHz radiofrequency-capacitive regional hyperthermia for pain relief of unresectable and recurrent colorectal cancer. Int J Hyperthermia 2006; 22:1-14. [PMID: 16423749 DOI: 10.1080/02656730500381152] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
PURPOSE The purpose of this study was to assess the pain relief in patients with unresectable and recurrent colorectal cancer treated with radiation plus 8 MHz radiofrequency-capacitive regional hyperthermia and to identify predictors of the good outcome. METHODS Between February 1986-May 2003, 41 patients with primarily unresectable and recurrent colorectal cancer that caused pain were treated with thermoradiotherapy at the hospital and retrospectively analysed. Radiotherapy was administered with a mean total radiation dose of 56 Gy. Hyperthermia was usually applied within 30 min after radiotherapy once or twice a week. For cooling of the skin surface, the overlay boluses were applied in addition to regular boluses. The external cooling unit has been used to reinforce the cooling ability of the overlay bolus and achieve strong surface cooling to reduce the preferential heating of the subcutaneous fat tissue and treat with more RF-output in 17 patients since January 1997. RESULTS Pain relief was obtained in 83% of the patients. Multi-variate analysis by logistic regression to evaluate the effects of certain factors on pain relief (complete response + good response) was strongly correlated with the presence of radiating pain to leg(s) (p < 0.05). The median follow-up was 18 months. The median duration of pain relief was 7.0 months. For the 27 patients in whom the tumour temperature was estimated, the median duration of pain relief was 14.6 months for the patients with a mean average tumour temperature of > 42.5 degrees C and 5.7 months for those of < 42.5 degrees C (p < 0.05). In the 18 patients with radiating pain to leg(s), use of strong superficial cooling and the higher numbers of hyperthermia treatments were better prognostic factors for the duration of pain relief (p < 0.01 and p < 0.05, respectively). CONCLUSIONS Radiotherapy with 8 MHz radiofrequency-capacitive regional hyperthermia provided an efficient, effective means on pain relief of treating unresectable and recurrent colorectal cancer. The duration of pain relief can be prolonged, if an adequate heating is achieved, especially in the patients with radiating pain to the leg(s).
Collapse
Affiliation(s)
- T Ohguri
- Department of Radiology, University of Occupational and Environmental Health, Kitakyushu, Japan.
| | | | | | | | | | | | | |
Collapse
|
7
|
Juffermans JHM, Hanssens PEJ, van Putten WLJ, van Rhoon GC, van Der Zee J. Reirradiation and hyperthermia in rectal carcinoma: a retrospective study on palliative effect. Cancer 2003; 98:1759-66. [PMID: 14534894 DOI: 10.1002/cncr.11719] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND The objective of this study was to evaluate the palliative effect of reirradiation and hyperthermia in patients with unresectable, recurrent colorectal carcinoma. METHODS The medical records of 54 patients with unresectable, recurrent colorectal carcinoma that caused pain and who were treated with reirradiation and hyperthermia, were evaluated retrospectively. Previous radiotherapy was given up to a total dose ranging from 25-70 grays (Gy). The median interval between prior radiotherapy and reirradiation was 22 months (range, 4-97 months). The total reirradiation dose varied from 24 Gy to 32 Gy given in fractions of 4 Gy twice weekly. Three or four hyperthermia treatments were given once weekly. Toxicity was registered. The influence of World Health Organization (WHO) performance status, maximum tumor dimension, and time between first radiotherapy and reirradiation on therapeutic outcome was evaluated. The results of this study were compared with published results on patients who received radiotherapy with or without hyperthermia. RESULTS Forty-seven patients (87%) completed the planned treatment schedule. The maximum toxicity was Grade 2. All patients were evaluated for palliative effect. The median follow-up was 10 months. A good or complete palliative effect was achieved in 72% of patients for a median duration of 6 months. Patients who had a better WHO performance status, smaller tumors, and a longer interval between first radiotherapy and reirradiation had slightly better outcomes, although none of those parameters reached statistical significance. CONCLUSIONS The described combined treatment was feasible and well tolerated. Comparison of results from radiotherapy plus hyperthermia with results after radiotherapy alone suggested that additional hyperthermia prolonged the duration of palliation. Firm proof of the contribution of hyperthermia will require performing a Phase III study.
Collapse
Affiliation(s)
- Jorine H M Juffermans
- Department of Radiation Oncology, Hyperthermia Unit, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
| | | | | | | | | |
Collapse
|
8
|
Abstract
BACKGROUND In order to improve the clinical results of rectal cancer, hyperthermia has been prescribed in combination with chemotherapy and radiotherapy. The techniques of hyperthermia and their clinical applications to rectal cancer were reviewed. METHODS The development of heating devices has been intensively investigated, including external heating devices, intraluminal heating devices, circulation of warmed saline solution, and whole body hyperthermia. RESULTS Nonrandomized and randomized trials for rectal cancer have demonstrated an improved local response with the combined use of hyperthermia and conventional treatments. A preoperative therapy with hyperthermia increased resectability and decreased local recurrence, resulting in the improvement of the postoperative prognosis. There were no major postoperative complications related to the preoperative treatment. A lower incidence of local recurrence was observed in groups that underwent intra- or postoperative hyperthermia treatment, as compared with control groups. In cases with unresectable or local recurrent rectal cancer, hyperthermia achieved a local tumor regression and prolonged pain relief. CONCLUSIONS These clinical data suggest that hyperthermia combined with radiation or chemotherapy demonstrates great promise for the treatment of patients with carcinoma of the rectum.
Collapse
Affiliation(s)
- Shinji Ohno
- Department of Breast Surgery, National Kyushu Cancer Center, Fukuoka, Japan
| | | | | | | |
Collapse
|
9
|
Minsky BD. Management of Locally Unresectable Rectal Cancer. COLORECTAL CANCER 2002. [DOI: 10.1007/978-1-59259-160-2_12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Harima Y, Nagata K, Harima K, Ostapenko VV, Tanaka Y, Sawada S. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. Int J Hyperthermia 2001; 17:97-105. [PMID: 11252361 DOI: 10.1080/02656730010001333] [Citation(s) in RCA: 151] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
To clarify the role of thermoradiotherapy for FIGO Stage IIIB cervical carcinomas, both the clinical response and survival of patients treated with radio- or thermoradiotherapy were investigated. Forty patients with Stage IIIB uterine cervix carcinoma were treated with external beam irradiation to the pelvis, combined with iridium 192 high-dose-rate intracavitary brachytherapy. All patients were divided randomly into the following two groups: the radiotherapy (RT) group of 20 patients, who underwent radiotherapy alone; and the thermoradiotherapy (TRT) group of 20 patients, who underwent three sessions of hyperthermia in addition to radiotherapy. The primary endpoint of this study was local complete response and survival. A complete response was achieved in 50% (10 of 20) in the RT group versus 80% (16 of 20) in the TRT group (p = 0.048). The 3-year overall survival and disease-free survival of the patients who were treated with TRT (58.2 and 63.6%) were better than those of the patients treated with RT (48.1 and 45%), but these differences were not significant. The 3-year local relapse-free survival of the patients who were treated with TRT (79.7%) was significantly better than that of the patients treated with RT (48.5%) (p = 0.048). TRT, as delivered in this trial, was well tolerated and did not significantly add to either the relevant clinical acute or long-term toxicity over radiation alone. TRT resulted in a better treatment response and 3-year local relapse-free survival rate than RT for patients with FIGO Stage IIIB cervical carcinoma.
Collapse
Affiliation(s)
- Y Harima
- Department of Radiology, Kansai Medical University, Moriguchi, Osaka, Japan.
| | | | | | | | | | | |
Collapse
|
11
|
Hehr T, Budach W, Lamprecht U, Paulsen F, Gromoll C, Bamberg M. Appendicitis during locoregional thermoradiotherapy of advanced or recurrent rectal and cervical cancer, a report of two cases. Int J Hyperthermia 1999; 15:487-94. [PMID: 10598946 DOI: 10.1080/026567399285486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
Abstract
INTRODUCTION Local tumour control after irradiation alone for advanced, inoperable carcinomas of the bladder and rectum or inoperable recurrent cervical carcinoma is usually disappointing. Both preclinical and clinical studies reported improvements by adding hyperthermia to radiotherapy. Reports for phase II/III trials do not indicate any enhanced side effects. However, two cases of acute suppurating appendicitis were observed in a series of patients treated with deep regional hyperthermia. MATERIALS, METHODS AND RESULTS Eighty patients with advanced, inoperable, or recurrent rectal or recurrent cervical tumours were treated with deep regional hyperthermia (313 sessions) in addition to radiotherapy between September 1995 and October 1998. The treatment for two of these patients (2.5%) had to be discontinued after the fourth/second hyperthermia treatments at 19.8/10.8 Gy total dose, respectively, for symptoms of pain in the right pelvis and elevated rectal temperature. Both patients underwent laparotomy and were found to have suppurative appendicitis. In addition to the retrocoecal location in both patients, evidence of preexisting chronic appendicitis, and appendiceal faecalith were observed in each patient. CONCLUSION The development of acute appendicitis in 2.5% of patients during a course of deep regional thermoradiotherapy for pelvic tumour is much higher than the expected incidence of appendicitis in the general population (< 1/1000) (Korner et al. 1997). An enhanced risk of suppurative appendicitis in patients undergoing pelvic thermoradiotherapy cannot be excluded, especially in retrocoecal located appendices with obstructed appendix lumen from preexisting chronic appendicitis or faecalith.
Collapse
Affiliation(s)
- T Hehr
- Department of Radiotherapy and Oncology, University of Tübingen, CRONA, Tuebingen, Germany.
| | | | | | | | | | | |
Collapse
|
12
|
Wust P, Fähling H, Helzel T, Kniephoff M, Wlodarczyk W, Mönich G, Felix R. Design and test of a new multi-amplifier system with phase and amplitude control. Int J Hyperthermia 1998; 14:459-77. [PMID: 9789770 DOI: 10.3109/02656739809018248] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The clinical relevance of the radiofrequency regional hyperthermia (RF-RHT) as an adjuvant cancer therapy grows continuously. Simulation studies for optimization of RF-RHT based on the annular phased array systems have shown a significant improvement of power deposition patterns with increasing number of channels. However, this probably requires higher phase accuracy and amplitude stability than are provided by presently used clinical systems, e.g. BSD-2000. Measurements performed on the BSD-200 electronic revealed phase inaccuracies up to +/- 20 degrees and errors in the power registration of +/- 20 W (up to +/- 50 W in the low power range). These errors are further enhanced by the mismatching of the external load (antenna applicator) and thermal instabilities. To achieve the required phase accuracy and long-term stability in the prototype of a new amplifier system, single-sideband (SSB) mixing in combination with direct digital synthesizers (DDS), in-phase and quadrature-phase (IQ) processing and phase-lock loop (PLL) were used. In the DDS's the actual phase of the output signal of each channel is calculated in real-time. No analogue control loop is involved that may cause thermal offset or drift problems. Each DDS operates at a low intermediate frequency (IF) of 1 MHz. To transform the phase information of this IF signal into the desired RF band, SSB mixing-up is performed. A second frequency source, operating as a local oscillator (LO) in the RF band, is required for this technique. Also, the frequency adjustment of the desired RF signal is performed in the LO. These phase and frequency adjustment units are followed by the high efficiency AB-class solid state amplifier unit. The phase and power level stability of the amplifier are controlled by means of digital PLL structures in conjunction with look-up tables. For this control test signals are coupled out by means of directional couplers. The phase control is based on very sensitive phase comparison. These digital control loops are programmable and allow the implementation of different control algorithms. The achieved long-term accuracy (95% confidence interval) is +/- 1-3 W for output power levels ranging from 10-100 W, and +/- 1 degree for phase differences between each channel and a reference signal at a constant power level, and +/- 1.5 degrees for phase difference values at variable power levels between 10-100 W. In conclusion, the new amplifier system is smaller and more efficient than presently available commercial systems.
Collapse
Affiliation(s)
- P Wust
- Department of Radiology, Charité Medical School-Campus Virchow-Klinikum, Humboldt University at Berlin, Germany
| | | | | | | | | | | | | |
Collapse
|
13
|
Rau B, Wust P, Hohenberger P, Löffel J, Hünerbein M, Below C, Gellermann J, Speidel A, Vogl T, Riess H, Felix R, Schlag PM. Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: a phase II clinical trial. Ann Surg 1998; 227:380-9. [PMID: 9527061 PMCID: PMC1191276 DOI: 10.1097/00000658-199803000-00010] [Citation(s) in RCA: 107] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE A prospective phase II study was performed to determine the feasibility and efficacy in terms of response rate, resectability, and morbidity in patients with locally advanced rectal cancer who received preoperative regional hyperthermia combined with radiochemotherapy (HRCT). SUMMARY BACKGROUND DATA Recent studies suggest that preoperative radiochemotherapy in locally advanced rectal cancer can induce downstaging, but after resection the incidence of local recurrences remains high. Hyperthermia (HT) may add tumoricidal effects and improve the efficacy of radiochemotherapy in a trimodal approach. PATIENTS AND METHODS Thirty-seven patients with histologically proven rectal cancer and T3 or T4 lesions, as determined by endorectal ultrasound and computed tomography, entered the trial. 5-Fluorouracil (300-350 mg/m2) and leucovorin (50 mg) were administered on days 1 to 5 and 22 to 26. Regional HT using the SIGMA 60 applicator (BSD-2000) was given once a week before radiotherapy (45 Gy with 1.8-Gy fractions for 5 weeks). Surgery followed 4 to 6 weeks after completion of HRCT. RESULTS Preoperative treatment was generally well tolerated, with 16% of patients developing grade III toxicity. No grade IV complications were observed. The overall resectability rate was 32 of 36 patients (89%), and 31 resection specimens had negative margins (R0). One patient refused surgery. In 5 patients (14%), the histopathologic report confirmed no evidence of residual tumor (pCR). A partial remission (PR) was observed in 17 patients (46%). The survival rate after 38 months was 86%. In none of the patients was local recurrence detected after R0(L), but five patients developed distant metastases. CONCLUSION Preoperative HRCT is feasible and effective and may contribute to locoregional tumor control of advanced rectal cancer, which is to be proven in an ongoing phase III trial.
Collapse
Affiliation(s)
- B Rau
- Virchow Klinikum at the Humboldt University of Berlin, Division of Surgery and Surgical Oncology, Robert-Roessle Hospital and Tumor Institute, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Wallace HJ, Willett CG, Shellito PC, Coen JJ, Hoover HC. Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. J Surg Oncol 1995; 60:122-7. [PMID: 7564378 DOI: 10.1002/jso.2930600211] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Recurrent rectal or rectosigmoid cancer is a difficult therapeutic problem. A treatment program of external beam irradiation, surgery, and intraoperative irradiation has been used for 41 patients. The 5-year actuarial local control and disease-free survival of all 41 patients was 30% and 16%, respectively. Subset analysis demonstrated differences in outcome by extent of surgical resection. The 5-year actuarial local control and disease-free survival of 27 patients undergoing complete resection was 47% and 21%, respectively. By contrast, the outcome of 14 patients undergoing partial resection was poor, with a 5-year actuarial local control and survival of 21% and 7%, respectively. Late complications included soft tissue or peripheral nerve injury, with many of these resolving within 4-18 months. Local control and disease-free survival rates are favorable in comparison with the results achieved by aggressive surgery. Patients who achieve a gross total resection at intraoperative irradiation have a markedly better prognosis than that of patients with residual gross disease.
Collapse
Affiliation(s)
- H J Wallace
- Department of Radiation Oncology, Massachusetts General Hosptial, Boston 02114, USA
| | | | | | | | | |
Collapse
|
15
|
Nagata Y, Hiraoka M, Nishimura Y, Masunaga S, Akuta K, Li YP, Koishi M, Mitsumori M, Okuno Y, Takahashi M. Clinical experiences in the thermoradiotherapy for advanced gastric cancer. Int J Hyperthermia 1995; 11:501-10. [PMID: 7594804 DOI: 10.3109/02656739509022485] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Recurrent and/or inoperable gastric cancer has been treated by thermoradiotherapy at Kyoto University Hospital since 1983. In the present study, the efficacy of hyperthermia (using radiofrequency capacitive heating) plus radiotherapy for gastric cancer was evaluated in 21 patients with local recurrence, abdominal wall metastases, peritonitis carcinomatosis or paraaortic node metastases. The intratumour temperature was measured using a microthermocouple thermometer. The means of the maximum, average, and minimum intratumour temperature were 43.5, 42.1, and 41.1 degrees C respectively. The local tumour response was evaluated using computed tomography (CT). The local response rate (complete regression plus partial regression/all tumours) was 88.9%, which seemed to be higher than that of other reports using thermochemotherapy or radiotherapy alone. The one-year cumulative survival rate was 39.1%.
Collapse
Affiliation(s)
- Y Nagata
- Department of Radiology, Faculty of Medicine, Kyoto University, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
72 patients with either unresectable or pelvic recurrence of colorectal cancer were treated with combined radiotherapy and locoregional hyperthermia. Radiation doses were 50 Gy or more in patients not previously treated with radiotherapy, and 32 Gy (8 x 4 Gy) in patients who had previously received radiotherapy. Hyperthermia was administered within 30 min of irradiation, and the aim was to give four to six sessions once or twice a week, intending to reach temperatures of at least 41 degrees C over 30 min. The mean of all the minimum (TMIN), maximum (TMAX) and median (TMED) intratumoral temperatures were 39.6, 41.1 and 40.2 degrees C, respectively. Toxicity during hyperthermia treatment consisted mainly of local pain within the heated field (33%) and general discomfort (17%). In 17% of the patients, the hyperthermic treatment was prematurely stopped. Palliation was achieved in 75% of patients with a mean duration of 12 months. The percentage of palliated patients was higher when higher radiation doses were administered. No correlation between palliative effect and thermal parameters was found. A computed tomography scan proved objective remission was obtained in 11 patients (15%). Median survival was 11 months, and 17% of the patients were alive at 3 years. The literature on combined radiotherapy and hyperthermia in colorectal cancer is reviewed. From this review and our own data, it is concluded that thermoradiotherapy is feasible. Acute and late toxicity are not major problems, although pain and general discomfort hamper hyperthermic treatment. The most disappointing fact is that, with the available hyperthermia equipment, the increase in intratumoral temperature does not reach, in general, the therapeutic range.
Collapse
Affiliation(s)
- D González González
- Department of Radiotherapy, Academic Medical Centre, University of Amsterdam, The Netherlands
| | | | | |
Collapse
|
17
|
Hiraoka M, Nishimura Y, Nagata Y, Mitsumori M, Okuno Y, Li PY, Takahashi M, Masunaga S, Akuta K, Koishi M. Clinical results of thermoradiotherapy for soft tissue tumours. Int J Hyperthermia 1995; 11:365-77. [PMID: 7636323 DOI: 10.3109/02656739509022472] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Thirty-one unresectable and/or recurrent soft tissue tumours in 27 patients underwent hyperthermia in combination with radiation therapy. Locoregional hyperthermia was administered once or twice a week for 40-60 min to a total of 2-14 sessions using RF capacitive or microwave heating equipment. Radiation therapy was given 10-20 min before hyperthermia at doses of 20.8 to 70 Gy. The mean +/- SD of the maximum, average, and minimum intratumour temperatures was 44.0 +/- 2.9 degrees C, 42.3 +/- 1.6 degrees C, 40.1 +/- 1.1 degree C respectively, and that of the percentage of the intratumour points that exceeded 41 and 43 degrees C was 66.0 +/- 33.6, and 31.0 +/- 26.1 respectively. Of the 31 tumours treated, 13 (42%) showed CR (complete regression), 10 (32%) PR (> 50 and < 100% regression) and 8 (26%) NC (< 50% regression). Since intratumour low density areas on post-treatment CT scans have been demonstrated to be a useful parameter for assessing tumour response to thermoradiotherapy, the presence of low density areas was also assessed. Low density areas were classified into the following three categories according to the percent area occupied in the maximal cross-section of the tumour: type I, < 50%, type II, 50-80%; type III, > 80%. Of 20 tumours evaluable, 6 (30%) exhibited type III change, 11 (55%) type II and 3 (15%) type I. All of the type III tumours demonstrated a marked response on follow-up or histopathological examination. The major complication associated with treatment was skin ulcer in two patients. The five-year survival of the total 27 patients and 18 patients who had no distant metastases at the start of treatment was 32 and 48% respectively. These results indicate the clinical benefit of thermoradiotherapy using RF capacitive or microwave equipment for locally advanced and/or recurrent soft tissue tumours.
Collapse
Affiliation(s)
- M Hiraoka
- Department of Radiology, Faculty of Medicine, Kyoto University, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
Radiation treatment is widely used in the management of adenocarcinomas of the rectum, either alone or more frequently as part of multimodality treatment protocols. External beam radiation is capable of eradicating about one-third of bulky but mobile primary rectal cancers and is an alternative to be considered when standard surgery is not possible. Endorectal irradiation, either alone or combined with external beam treatment, has proved highly effective for selected superficial cancers of the distal rectum. Irradiation alone or in conjunction with cytotoxic chemotherapy appears to reduce the risk of tumor progression at the primary site or in regional lymph nodes when combined with local surgical excisions that preserve anorectal function. The treatment of recurrent and metastatic cancer frequently provides palliation, although cure by irradiation is rare.
Collapse
Affiliation(s)
- B J Cummings
- Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Ontario, Canada
| |
Collapse
|
19
|
|
20
|
Hiraoka M, Nishimura Y, Nagata Y, Mitsumori M, Okuno Y, Li PY, Abe M, Takahashi M, Masunaga S, Akuta K. Site-specific phase I, II trials of hyperthermia at Kyoto University. Int J Hyperthermia 1994; 10:403-10. [PMID: 7930807 DOI: 10.3109/02656739409010285] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Site-specific phase I, II trials of locoregional hyperthermia undertaken at Kyoto University are briefly reviewed. Thermometry analysis demonstrated the usefulness of RF (radiofrequency) capacitive heating equipment in the treatment of various subsurface or deep-seated tumours including locally advanced breast cancers, soft tissue tumours, lung cancers involving the chest wall, liver tumours, unresectable or recurrent colorectal cancers, and invasive urinary bladder cancers. The difficulty in heating whole tumour volume or hypervascular tumours to therapeutic temperatures was also shown. Non-randomized trials for locally advanced breast cancers, unresectable or recurrent colorectal cancers and invasive urinary bladder cancers demonstrated a higher response rate in thermoradiotherapy than in radiotherapy alone. The complications associated with treatment were not generally serious except for chronic bowel damages in a trial for colorectal cancers. These promising phase I, II trials encourage the future phase III trials.
Collapse
Affiliation(s)
- M Hiraoka
- Department of Radiology, Faculty of Medicine, Kyoto University, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Overgaard M, Bertelsen K, Dalmark M, Gadeberg CC, von der Maase H, Overgaard J, Sell A. A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-fluorouracil in the treatment of locally recurrent or inoperable colorectal carcinoma. Acta Oncol 1993; 32:547-53. [PMID: 8217239 DOI: 10.3109/02841869309096116] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The effect of radiotherapy alone or given simultaneously with 5-FU in the treatment of locally recurrent or inoperable colorectal carcinoma was investigated in a randomized feasibility trial. Twenty-nine patients were randomized to radiotherapy alone (50 Gy/5 weeks + 10-20 Gy boost), and 30 patients to the same radiotherapy with weekly 5-FU (600 mg/m2) given before treatment every Monday during the first 5 weeks. The two groups were comparable with regard to age, sex, previous treatment, symptoms, tumour size and performance status. Treatment compliance to radiotherapy was the same in both groups with 87% receiving at least 50 Gy. Drug treatment was completed in 18/30 patients. Overall the treatment resulted in a significant palliative effect in 73% of evaluable patients with a median duration of 26 months, and objective response in 32% (8 CR, 11 PR), with a median duration of 18 months. The 3-year actuarial survival rate was 9% (median 12 months). Only patients who achieved CR became long-time survivors (63% 3-year actuarial survival). Similarly, performance status had a strong association with survival. Multivariate analysis showed complete response and high performance status to be the only parameters having prognostic influence on survival. Addition of 5-FU did neither influence the objective or symptomatic response, nor the development of distant metastases. However, addition of the drug resulted in an apparent increase in the frequency of severe acute radiation complications (33% vs. 13% after irradiation alone).
Collapse
Affiliation(s)
- M Overgaard
- Department of Oncology, Aarhus University Hospital, Denmark
| | | | | | | | | | | | | |
Collapse
|